3161-68-0

Basic information

• Product Name: Ethyl 4-Methyl-2-(MethylaMino)thiazole-5-carboxylate
• Synonyms: Ethyl 4-Methyl-2-(MethylaMino)thiazole-5-carboxylate;5-Thiazolecarboxylic acid, 4-methyl-2-(methylamino)-, ethyl ester
• CAS NO: 3161-68-0
• Molecular Formula: C8H12N2O2S
• Molecular Weight: 200.25808
• Mol File: 3161-68-0.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 290.9 °C at 760 mmHg
• Flash Point: 129.7 °C
• Appearance: /
• Density: 1.234 g/cm³
• Vapor Pressure: 0.00201mmHg at 25°C
• Refractive Index: 1.574
• CAS DataBase Reference: Ethyl 4-Methyl-2-(MethylaMino)thiazole-5-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 4-Methyl-2-(MethylaMino)thiazole-5-carboxylate(3161-68-0)
• EPA Substance Registry System: Ethyl 4-Methyl-2-(MethylaMino)thiazole-5-carboxylate(3161-68-0)

Safety Data

• Hazardous Substances Data: 3161-68-0(Hazardous Substances Data)

Usage

General Description

Ethyl 4-Methyl-2-(MethylaMino)thiazole-5-carboxylate is a chemical compound with the molecular formula C9H12N2O2S. It is a thiazole derivative with a methylamino substituent at the 2-position and an ethyl ester at the 5-position. Ethyl 4-Methyl-2-(MethylaMino)thiazole-5-carboxylate has applications in pharmaceutical and chemical research, as well as in the synthesis of various organic compounds. It has been studied for its potential biological activities, including antimicrobial and antifungal properties. Additionally, it is used as a building block in the synthesis of other complex organic molecules due to its versatile reactivity.

InChI:InChI=1/C8H12N2O2S/c1-4-12-7(11)6-5(2)10-8(9-3)13-6/h4H2,1-3H3,(H,9,10)

Upstream product

• 25348-92-9 Bis-(methylformamidine) disulphide dihydrobromide 
• 141-97-9 ethyl acetoacetate 
• 598-52-7 1-(methyl)-thiourea 
• 609-15-4 ethyl 2-chloro-3-oxo-butyrate 
• 1369787-44-9 C₁₆H₁₈N₂O₄S 

Relevant articles and documents

Preparation method and application of N-(pyrimidine-2-yl) coumarin-7-amine derivative as protein kinase inhibitor

The invention discloses a cyclin-dependent kinase inhibitor. The cyclin-dependent kinase inhibitor comprises an N-(pyrimidine-2-yl) coumarin-7-amine derivative shown as a general formula (I). In-vitropharmacodynamic tests prove that the compound has a high-selectivity inhibition effect on CDK9 kinase, and can be applied to reducing or inhibiting the activity of CDK9 kinase in cells. The inventionalso discloses a preparation method of the inhibitor and application of the inhibitor in drugs for CDK family kinase mediated diseases, especially hyperproliferative diseases, virus-induced infectious diseases and cardiovascular diseases.

One-Pot Telescoped Synthesis of Thiazole Derivatives from β-Keto Esters and Thioureas Promoted by Tribromoisocyanuric Acid

A simple and efficient one-pot protocol has been developed for the synthesis of thiazole derivatives from readily available starting materials. Tribromoisocyanuric acid was successfully used for α-monohalogenation of β-keto esters in aqueous medium, which

Substituted 4-(thiazol-5-yl)-2-(phenylamino)pyrimidines are highly active CDK9 inhibitors: Synthesis, X-ray crystal structures, structure-activity relationship, and anticancer activities

Cancer cells often have a high demand for antiapoptotic proteins in order to resist programmed cell death. CDK9 inhibition selectively targets survival proteins and reinstates apoptosis in cancer cells. We designed a series of 4-thiazol-2-anilinopyrimidine derivatives with functional groups attached to the C5-position of the pyrimidine or to the C4-thiazol moiety and investigated their effects on CDK9 potency and selectivity. One of the most selective compounds, 12u inhibits CDK9 with IC50 = 7 nM and shows over 80-fold selectivity for CDK9 versus CDK2. X-ray crystal structures of 12u bound to CDK9 and CDK2 provide insights into the binding modes. This work, together with crystal structures of selected inhibitors in complex with both enzymes described in a companion paper,(34) provides a rationale for the observed SAR. 12u demonstrates potent anticancer activity against primary chronic lymphocytic leukemia cells with a therapeutic window 31- and 107-fold over those of normal B- and T-cells.